CD38 and systemic sclerosis: Although further studies are necessary to provide additional proof-of-concept evidence regarding the pathogenic role and the possible targeting of CD38, nevertheless in SSc there is an urgent need to find effective treatments that aim at restoring the deranged B cell response.